Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-09-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于以票据、应收账款、理财产品等资产质押开展融资类业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's plan to use assets such as bank acceptance bills, accounts receivable, and financial products as collateral to conduct financing business. It details the business overview, specific plan, purpose, risk and mitigation measures, decision procedures, and independent directors' opinions. The document is relatively short (1485 characters) and focuses on informing shareholders and the public about a financing activity involving asset pledges. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full financial report but an announcement about financing activities and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-09-28 Chinese
东海证券股份有限公司关于昆药集团股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Donghai Securities regarding Kunming Pharmaceutical Group Co., Ltd.'s use of temporarily idle raised funds for cash management. It references regulatory approvals, fundraising details, investment projects, and compliance with relevant securities regulations. The document includes audit opinions and confirms that the use of idle funds for low-risk financial products complies with legal and regulatory requirements. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or a certification letter. Instead, it is a standalone audit/verification report related to the use of raised funds, which fits the category of Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content and detailed verification, not merely an announcement of a report, so it is not an RPA or RNS. Therefore, the best classification is AR with high confidence. Q3 2021
2021-09-28 Chinese
昆药集团关于利用闲置自有资金进行投资理财业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of idle funds for investment in financial products. It details the board and supervisory committee approvals, investment purpose, authorization limits, risk analysis, and the need for shareholder approval. The document is a formal announcement of a financing-related decision but does not contain financial statements or detailed financial results. It is not a full financial report, earnings release, or management report. It is also not a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management decisions.
2021-09-28 Chinese
昆药集团关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange concerning the management and use of raised funds. The document details the amount of funds raised through public and non-public stock issuance, the investment projects funded, and the plan to invest idle funds in low-risk financial products. It includes opinions from independent directors, the supervisory board, and the sponsoring institution, and states that the matter requires approval at a shareholders' meeting. The document is a formal announcement about the company's financing fund management and investment plans, not a full financial report or audit. It is also relatively short (4378 characters) and does not contain financial statements or detailed financial analysis. Therefore, it fits best into the category of Capital/Financing Update (CAP), as it updates on the company's fundraising and capital usage activities.
2021-09-28 Chinese
昆药集团关于公司获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration (国家药品监督管理局). It details the drug's registration information, market context, and potential impact on the company. The document is short (1325 characters) and is an announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category, as it informs investors about a regulatory milestone affecting the company. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-09-15 Chinese
昆药集团关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase wealth management products. It details the amounts, types, and terms of financial products purchased with idle raised funds, the approval procedures, risk controls, and the impact on the company. The document includes financial figures but does not present a comprehensive financial report or detailed financial statements. It is a regulatory disclosure about the company's use of raised funds for cash management purposes, consistent with regulatory requirements for listed companies in China. The document is not an annual or interim report, earnings release, or audit report. It is a specific update on capital/financing activities related to the use of raised funds. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-08-25 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.